Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 3
1983 1
1984 2
1986 3
1987 2
1988 3
1989 2
1990 1
1991 2
1992 3
1993 4
1994 11
1995 5
1996 6
1997 9
1998 4
1999 3
2000 12
2001 11
2002 23
2003 27
2004 35
2005 50
2006 70
2007 71
2008 99
2009 101
2010 134
2011 172
2012 252
2013 322
2014 385
2015 479
2016 411
2017 530
2018 699
2019 747
2020 883
2021 1082
2022 1265
2023 1225
2024 619

Text availability

Article attribute

Article type

Publication date

Search Results

8,732 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for jiang jiang yin
Your search for Jiangjiang Yin retrieved no results
Retraction.
[No authors listed] [No authors listed] J Cell Biochem. 2021 Nov;122 Suppl 1:S87. doi: 10.1002/jcb.30055. Epub 2021 Jun 30. J Cell Biochem. 2021. PMID: 34191333
Retraction: "Microrna-139-5p inhibits epithelial-mesenchymal transition and fibrosis in post-menopausal women with interstitial cystitis by targeting LPAR4 via the PI3K/Akt signaling pathway," by Chen Jiang, Zhen Tong, Wei-Lin Fang, Qi-Bo Fu, Yin-Jun Gu, Ting-Ting L …
Retraction: "Microrna-139-5p inhibits epithelial-mesenchymal transition and fibrosis in post-menopausal women with interstitial cystitis by …
Retraction.
[No authors listed] [No authors listed] J Cell Physiol. 2022 May;237(5):2593. doi: 10.1002/jcp.30714. Epub 2022 Mar 16. J Cell Physiol. 2022. PMID: 35297048
Retraction: "Long noncoding RNA ZBED3-AS1 induces the differentiation of mesenchymal stem cells and enhances bone regeneration by repressing IL-1beta via Wnt/beta-catenin signaling pathway," by Kongzu Hu, Wei Jiang, Heyan Sun, Zhenwei Li, Genxiang Rong, and Zongsheng Yi …
Retraction: "Long noncoding RNA ZBED3-AS1 induces the differentiation of mesenchymal stem cells and enhances bone regeneration by repressing …
Bis(N-benzoyl-N-phenyl-hydroxy-l-aminato-κO,O')dimethyl-tin(IV).
Jiang J, Dong L, Yin H. Jiang J, et al. Acta Crystallogr Sect E Struct Rep Online. 2011 Aug 1;67(Pt 8):m1029. doi: 10.1107/S160053681102561X. Epub 2011 Jul 6. Acta Crystallogr Sect E Struct Rep Online. 2011. PMID: 22090823 Free PMC article.
The Yin-Yang roles of protease-activated receptors in inflammatory signalling and diseases.
Zhuo X, Wu Y, Fu X, Liang X, Xiang Y, Li J, Mao C, Jiang Y. Zhuo X, et al. FEBS J. 2022 Jul;289(14):4000-4020. doi: 10.1111/febs.16406. Epub 2022 Mar 3. FEBS J. 2022. PMID: 35175692 Free article. Review.
PARs activation can trigger downstream intracellular signalling to modulate a variety of inflammatory responses in multiple systems, including nervous, respiratory, digestive, circulatory, urinary and immune systems. Importantly, there are the Yin-Yang effects, comprising …
PARs activation can trigger downstream intracellular signalling to modulate a variety of inflammatory responses in multiple systems, includi …
Neuroinflammation in Bilirubin Neurotoxicity.
Zhang F, Chen L, Jiang K. Zhang F, et al. J Integr Neurosci. 2023 Jan 5;22(1):9. doi: 10.31083/j.jin2201009. J Integr Neurosci. 2023. PMID: 36722237 Free article. Review.
Here, recent advances concerning neuroinflammation in bilirubin neurotoxicity are reported with a focus on the clinical characteristics of bilirubin neurotoxicity, including age-dependency, region-specificity and its yin-yang properties. Effects of neuroinflammation on blo …
Here, recent advances concerning neuroinflammation in bilirubin neurotoxicity are reported with a focus on the clinical characteristics of b …
Extracellular vesicles: Targeting the heart.
Yin X, Jiang LH. Yin X, et al. Front Cardiovasc Med. 2023 Jan 10;9:1041481. doi: 10.3389/fcvm.2022.1041481. eCollection 2022. Front Cardiovasc Med. 2023. PMID: 36704471 Free PMC article. Review.
Tianma Gouteng Yin Formula for treating primary hypertension.
Zhang HW, Tong J, Zhou G, Jia H, Jiang JY. Zhang HW, et al. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD008166. doi: 10.1002/14651858.CD008166.pub2. Cochrane Database Syst Rev. 2012. PMID: 22696374 Review.
BACKGROUND: Tianma Gouteng Yin Formula (TGYF) is widely used to treat hypertension-related symptoms in clinical practice in East Asia. ...OBJECTIVES: To assess the efficacy and safety of Tianma Gouteng Yin Formula for treating primary hypertension compared to placeb …
BACKGROUND: Tianma Gouteng Yin Formula (TGYF) is widely used to treat hypertension-related symptoms in clinical practice in East Asia …
COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas.
Ren X, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, Yang Y, He J, Ma W, He J, Wang P, Cao Q, Chen F, Chen Y, Cheng X, Deng G, Deng X, Ding W, Feng Y, Gan R, Guo C, Guo W, He S, Jiang C, Liang J, Li YM, Lin J, Ling Y, Liu H, Liu J, Liu N, Liu SQ, Luo M, Ma Q, Song Q, Sun W, Wang G, Wang F, Wang Y, Wen X, Wu Q, Xu G, Xie X, Xiong X, Xing X, Xu H, Yin C, Yu D, Yu K, Yuan J, Zhang B, Zhang P, Zhang T, Zhao J, Zhao P, Zhou J, Zhou W, Zhong S, Zhong X, Zhang S, Zhu L, Zhu P, Zou B, Zou J, Zuo Z, Bai F, Huang X, Zhou P, Jiang Q, Huang Z, Bei JX, Wei L, Bian XW, Liu X, Cheng T, Li X, Zhao P, Wang FS, Wang H, Su B, Zhang Z, Qu K, Wang X, Chen J, Jin R, Zhang Z. Ren X, et al. Cell. 2021 Nov 11;184(23):5838. doi: 10.1016/j.cell.2021.10.023. Cell. 2021. PMID: 34767776 Free PMC article. No abstract available.
HPLC-MS and Network Pharmacology Analysis to Reveal Quality Markers of Huo-Xue-Jiang-Tang Yin, a Chinese Herbal Medicine for Type 2 Diabetes Mellitus.
Chen Q, Zhao Y, Li M, Zheng P, Zhang S, Li H, Chen J. Chen Q, et al. Evid Based Complement Alternat Med. 2021 Mar 15;2021:1072975. doi: 10.1155/2021/1072975. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 33790972 Free PMC article.
Huo-Xue-Jiang-Tang Yin (HXJTY) is a Chinese medicine formulation, which has been widely used for the treatment of various lipometabolism- and glycometabolism-related diseases in clinics. ...
Huo-Xue-Jiang-Tang Yin (HXJTY) is a Chinese medicine formulation, which has been widely used for the treatment of various lipo …
8,732 results